

FORM 7

MONTHLY PROGRESS REPORT

For November 2019

Name of Listed Issuer: Liberty Health Sciences Inc. (the "Issuer" or "Company").

Trading Symbol: LHS

Number of Outstanding Listed Securities: 345,290,635 common shares

Date: December 6, 2019

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Company intends to continue to evaluate strategic avenues for growth including, but not limited to, evaluating targets for expansion in key U.S. states that have approved medical use of marijuana and meet its stringent investment criteria.

2. Provide a general overview and discussion of the activities of management.

In Florida, in addition to completing the remaining retrofit activities at its Liberty 360° Innovation Campus in Gainesville, management continues to seek and open potential dispensary sites.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None to report in the month November.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None to report in the month of November.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None to report in the month of November.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None to report in the month of November.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None to report in the month of November.

8. Describe the acquisition of new customers or loss of customers.

The Company continues to grow its number of patients as the overall Florida market increases in terms of registered patients and as the Company expands its footprint in the state. The Florida market has also reacted positively to Liberty's whole flower products and continues to assist to expand Liberty's customer base.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

None to report in the month of November.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

The Company continues to add personnel in the areas of patient care and processing in the Florida operations and dispensaries with the expected opening of additional dispensaries over the next 30-60 days.

There were no significant terminations or lay-offs in the month of November.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None to report in the month of November.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None to report in the month November.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

No new debt to report for the month of November.

14. Provide details of any securities issued and options or warrants granted.

None to report in the month November.

15. Provide details of any loans to or by Related Persons.

None to report in the month of November.

16. Provide details of any changes in directors, officers or committee members.

None to report in the month of November.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

In November, Florida Senator Perry Thurston has introduced SB 212, which would prohibit retail facilities from producing their own products, as they are currently required to do. The bill further seeks to curtail the vertical integration of the market by limiting the number of medical marijuana treatment centers with whom a retail facility can be associated and disallowing treatment centers from owning or operating dispensaries. In addition, the bill would prohibit applicants listed as an owner, board member, officer, or manager from being listed on more than one licensure application for medical marijuana retail facilities. Finally, SB 212 would identify applicants with strong diversity plans and implement educational programs to help them obtain licensure.

Also, in November, Florida State Representative Anthony Sabatini introduced HB 149 which would require entities that "cultivate, process, transport, or dispense marijuana" to be licensed as medical marijuana treatment centers. By changing of the language from "and" to "or" indicates the same company does not need to plant marijuana, distribute it, and do everything in between. This bill would remove the current limits on the number of applicants allowed to be approved within a specific timeframe and geographic area. Notably, HB 149 states that preference must be given to minority farmers and companies that currently process, concentrate, and can citrus fruits. HB 149 would also require a performance bond of \$5 million for each applicant, or \$2 million if the applicant serves 1,000 or more patients.

Another bill filled by Senator Janet Cruz and Rep. Adam Hattersley would waive the registration fees for veterans. The goal is to increase their access to treatments other than opioids. If passed, this would be the first medical marijuana discount offered in Florida.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. To the best of the undersigned's knowledge and belief, as of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that, to the best of the undersigned's knowledge and belief, the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. To the best of the undersigned's knowledge and belief, all of the information in this Form 7 Monthly Progress Report is true.

Dated December 6, 2019.

Sheri Cholodofsky
Name of Director or Senior Officer

"Sheri Cholodofsky"
Signature

CFO
Official Capacity

<i>Issuer Details</i> Name of Issuer Liberty Health Sciences Inc.	For Month End November 30, 2019	Date of Report YY/MM/DD 19/12/06
Issuer Address 78 Gwendolen Crescent		
City/Province/Postal Code Toronto, ON, Canada M2N 2L7	Issuer Fax No.	Issuer Telephone No.
Contact Name Sheri Cholodofsky	Contact Position CFO	Contact Telephone 833 254 4877
Contact Email Address scholodofsky@libertyhealthsciences.com	Web Site Address https://libertyhealthsciences.com/	